DANIRIXIN
Danirixin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
15 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 6 | 4 | — | — | — | 10 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 3 | — | — | — | 3 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 3 | — | — | — | 3 |
| Virus diseases | D014777 | — | B34 | — | 2 | — | — | — | 2 |
| Human influenza | D007251 | EFO_0007328 | J11.1 | — | 2 | — | — | — | 2 |
| Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | — | J06.9 | 2 | — | — | — | — | 2 |
| Respiratory syncytial virus infections | D018357 | EFO_1001413 | — | 1 | — | — | — | — | 1 |
| Nutritional status | D009752 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DANIRIXIN |
| INN | danirixin |
| Description | Danirixin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target C-X-C chemokine receptor type 2. |
| Classification | Small molecule |
| Drug class | chemokine (C-X-C motif) receptor 2 (CXCR2) modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)[C@H]2CCCNC2)c1O |
Identifiers
| PDB | — |
| CAS-ID | 954126-98-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039531 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | R318PGH5VP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CXCR2
CXCR2
Organism
Homo sapiens
Gene name
CXCR2
Gene synonyms
IL8RB
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 2
Protein synonyms
CD182, CDw128b, chemokine (CXC) receptor 2, CXC-R2, CXCR-2, CXCR2 gene for IL8 receptor type B, GRO/MGSA receptor, High affinity interleukin-8 receptor B, IL-8 receptor type 2, IL-8R B, interleukin 8 receptor type 2, interleukin 8 receptor, beta, interleukin-8 receptor type B
Uniprot ID
Mouse ortholog
Cxcr2 (12765)
C-X-C chemokine receptor type 2 (Q53X27)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 171 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use